All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Results from a phase II, non-randomized, open-label, single-arm study (PembroWM; NCT03630042) evaluating efficacy and safety of pembrolizumab, a PD-1 inhibitor, and rituximab combination therapy in the treatment of relapsed/refractory (R/R) Waldenstrom's macroglobulinemia (WM) were published by Kothari et al.1 in British Journal of Haematology. |
Key learnings: |
A total of 17 patients were included; 88% of patients were pretreated with covalent Bruton’s tyrosine kinase inhibitors (cBTKi) and 71% were refractory/intolerant to cBTKi. |
The primary endpoint was not met as overall response was only achieved in 7 patients (very good partial response, 1; partial response, 3; minor response, 3) at Week 24.
|
Median progression-free survival (PFS) was 13.6 months; 1- and 2-year PFS rates were 58.2% and 19.4%, respectively. |
Median overall survival (OS) was not reached; 1- and 2-year OS rates were 92.9% and 67%, respectively. |
The 1- and 2-year time to next treatment rates were 72.7% and 43.1%, respectively. |
Adverse events (AEs) were observed in 94% of patients.
|
There were no significant improvements in quality-of-life scores in the majority of patients, except for emotional (p = 0.02) and cognitive functioning (p = 0.03). |
The results indicate that the combination of pembrolizumab and rituximab is feasible and tolerable in patients with R/R WM, including those who have been heavily pretreated and are refractory to cBTKi. Further research is needed to explore the modulation of PD-1 axis in the management of WM. |
‘The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) and the Lymphoma Hub are working in collaboration for patients with Waldenstrom’s macroglobulinemia. This initiative aims to increase awareness of Waldenstrom's macroglobulinemia among healthcare professionals, patients, caregivers, and the patient advocacy community.
This initiative is funded by Cellectar Biosciences and Eli Lilly. All content is developed independently by SES in collaboration with an expert steering committee; funders are allowed no direct influence on the content of the hub.’
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox